Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2014 (2014), Article ID 563812, 7 pages
Research Article

Investigation of PACAP Fragments and Related Peptides in Chronic Retinal Hypoperfusion

1Department of Anatomy, PTE-MTA “Lendulet” PACAP Research Team, University of Pecs, Szigeti ut 12, Pecs 7624, Hungary
2Department of Medical Chemistry, University of Szeged, Dom Ter 8, Szeged 6720, Hungary
3Department of Experimental Zoology and Neurobiology, University of Pecs, Ifjusag Utja 6, Pecs 7624, Hungary
4Department of Ophthalmology, University of Pecs, Nyar Utca 8, Pecs 7624, Hungary
5Department of Sportbiology, University of Pecs, Ifjusag Utja 6, Pecs 7624, Hungary
6Janos Szentagothai Research Center, University of Pecs, Ifjusag Utja 20, Pecs 7624, Hungary

Received 20 January 2014; Accepted 24 March 2014; Published 12 May 2014

Academic Editor: Robert Gabriel

Copyright © 2014 Dora Werling et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Pituitary adenylate cyclase activating polypeptide (PACAP) has neuroprotective effects in different neuronal and retinal injuries. Retinal ischemia can be effectively modelled by permanent bilateral common carotid artery occlusion (BCCAO), which causes chronic hypoperfusion-induced degeneration in the entire rat retina. The retinoprotective effect of PACAP 1-38 and VIP is well-established in ischemic retinopathy. However, little is known about the effects of related peptides and PACAP fragments in ischemic retinopathy. The aim of the present study was to investigate the potential retinoprotective effects of different PACAP fragments (PACAP 4-13, 4-22, 6-10, 6-15, 11-15, and 20-31) and related peptides (secretin, glucagon) in BCCAO-induced ischemic retinopathy. Wistar rats (3-4 months old) were used in the experiment. After performing BCCAO, the right eyes of the animals were treated with PACAP fragments or related peptides intravitreal (100 pM), while the left eyes were injected with saline serving as control eyes. Sham-operated (without BCCAO) rats received the same treatment. Routine histology was performed 2 weeks after the surgery; cells were counted and the thickness of retinal layers was compared. Our results revealed significant neuroprotection by PACAP 1-38 but did not reveal retinoprotective effect of the PACAP fragments or related peptides. These results suggest that PACAP 1-38 has the greatest efficacy in ischemic retinopathy.